Poly [ADP Ribose] Polymerase 2 - Pipeline Review, H1 2020
Poly [ADP Ribose] Polymerase 2 - Pipeline Review, H1 2020
SUMMARY
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The latest report Poly [ADP Ribose] Polymerase 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 2 is an enzyme encoded by the PARP2 gene. It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in signaling pathway leading to the reparation of DNA strand breaks.
The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 3, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Endometrial Cancer, Fallopian Tube Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Breast Cancer, Peritoneal Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Metastatic Breast Cancer, Prostate Cancer, Small-Cell Lung Cancer, Gastric Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Malignant Mesothelioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Pancreatic Cancer, Pancreatic Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Bladder Cancer, Colorectal Cancer, Esophageal Cancer, Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Leiomyosarcoma, Lung Cancer, Mantle Cell Lymphoma, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Neuroblastoma, Non-Hodgkin Lymphoma, Oropharyngeal Cancer, Peritoneal Tumor, Renal Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Uterine Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Anaplastic Astrocytoma, B-Cell Chronic Lymphocytic Leukemia, Biliary Tumor, Bone Sarcoma, Brenner Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Clear Cell Squamous Cell Carcinoma, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Germ Cell Tumors, Germinomatous (Seminomatous) Germ Cell Tumors, Head And Neck Cancer, High-Grade Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Intestinal Cancer, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Liposarcoma, Low-Grade Glioma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Myelofibrosis, Myeloproliferative Disorders, Natural Killer Cell Lymphomas, Neuroendocrine Tumors, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Pancreatic Ductal Adenocarcinoma, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Polycythemia Vera, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sarcomas, Soft Tissue Sarcoma, T-Cell Lymphomas, Testicular Cancer, Ureter Cancer, Urethral Cancer and Uveal Melanoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The latest report Poly [ADP Ribose] Polymerase 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 2 is an enzyme encoded by the PARP2 gene. It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in signaling pathway leading to the reparation of DNA strand breaks.
The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 3, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Endometrial Cancer, Fallopian Tube Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Breast Cancer, Peritoneal Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Metastatic Breast Cancer, Prostate Cancer, Small-Cell Lung Cancer, Gastric Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Malignant Mesothelioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Pancreatic Cancer, Pancreatic Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Bladder Cancer, Colorectal Cancer, Esophageal Cancer, Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Leiomyosarcoma, Lung Cancer, Mantle Cell Lymphoma, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Neuroblastoma, Non-Hodgkin Lymphoma, Oropharyngeal Cancer, Peritoneal Tumor, Renal Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Uterine Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Anaplastic Astrocytoma, B-Cell Chronic Lymphocytic Leukemia, Biliary Tumor, Bone Sarcoma, Brenner Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Clear Cell Squamous Cell Carcinoma, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Germ Cell Tumors, Germinomatous (Seminomatous) Germ Cell Tumors, Head And Neck Cancer, High-Grade Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Intestinal Cancer, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Liposarcoma, Low-Grade Glioma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Myelofibrosis, Myeloproliferative Disorders, Natural Killer Cell Lymphomas, Neuroendocrine Tumors, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Pancreatic Ductal Adenocarcinoma, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Polycythemia Vera, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sarcomas, Soft Tissue Sarcoma, T-Cell Lymphomas, Testicular Cancer, Ureter Cancer, Urethral Cancer and Uveal Melanoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)
- The report reviews Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects
- The report assesses Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Overview
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
BeiGene Ltd
Clovis Oncology Inc
Convalife
GlaxoSmithKline Plc
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc
Ildong Pharmaceutical Co Ltd
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Oncology Venture U.S. Inc
Shanghai Acebright Pharmaceuticals Group Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Drug Profiles
2X-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABT-767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-0108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cediranib maleate + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceralasertib + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVL-218 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HWH-340 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDX-1197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPI-547 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niraparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pamiparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rucaparib camsylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-10914 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-3162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target NO and PARP 1, 2, 3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOMCL-9112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YHP-743 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Dormant Products
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Discontinued Products
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Product Development Milestones
Featured News & Press Releases
Appendix
Global Markets Direct Report Coverage
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Overview
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
BeiGene Ltd
Clovis Oncology Inc
Convalife
GlaxoSmithKline Plc
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc
Ildong Pharmaceutical Co Ltd
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Oncology Venture U.S. Inc
Shanghai Acebright Pharmaceuticals Group Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Drug Profiles
2X-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABT-767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-0108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cediranib maleate + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceralasertib + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVL-218 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HWH-340 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDX-1197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPI-547 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niraparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pamiparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rucaparib camsylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-10914 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-3162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target NO and PARP 1, 2, 3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOMCL-9112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YHP-743 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Dormant Products
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Discontinued Products
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Product Development Milestones
Featured News & Press Releases
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Products under Development by Companies, H1 2020 (Contd..11), H1 2020
Products under Development by Companies, H1 2020 (Contd..12), H1 2020
Products under Development by Companies, H1 2020 (Contd..13), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by BeiGene Ltd, H1 2020
Pipeline by Clovis Oncology Inc, H1 2020
Pipeline by Convalife, H1 2020
Pipeline by GlaxoSmithKline Plc, H1 2020
Pipeline by Hubei Bio-Pharmaceutical Industrial Technological Institute Inc, H1 2020
Pipeline by Ildong Pharmaceutical Co Ltd, H1 2020
Pipeline by Jeil Pharmaceutical Co Ltd, H1 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Pipeline by Oncology Venture U.S. Inc, H1 2020
Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H1 2020
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Products under Development by Companies, H1 2020 (Contd..11), H1 2020
Products under Development by Companies, H1 2020 (Contd..12), H1 2020
Products under Development by Companies, H1 2020 (Contd..13), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by BeiGene Ltd, H1 2020
Pipeline by Clovis Oncology Inc, H1 2020
Pipeline by Convalife, H1 2020
Pipeline by GlaxoSmithKline Plc, H1 2020
Pipeline by Hubei Bio-Pharmaceutical Industrial Technological Institute Inc, H1 2020
Pipeline by Ildong Pharmaceutical Co Ltd, H1 2020
Pipeline by Jeil Pharmaceutical Co Ltd, H1 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Pipeline by Oncology Venture U.S. Inc, H1 2020
Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H1 2020
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
AbbVie Inc
AstraZeneca Plc
BeiGene Ltd
Clovis Oncology Inc
Convalife
GlaxoSmithKline Plc
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc
Ildong Pharmaceutical Co Ltd
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Oncology Venture U.S. Inc
Shanghai Acebright Pharmaceuticals Group Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
AbbVie Inc
AstraZeneca Plc
BeiGene Ltd
Clovis Oncology Inc
Convalife
GlaxoSmithKline Plc
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc
Ildong Pharmaceutical Co Ltd
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Oncology Venture U.S. Inc
Shanghai Acebright Pharmaceuticals Group Co Ltd
Shanghai De Novo Pharmatech Co Ltd
